AVITA Medical, Inc. (ASX:AVH)
Australia · Delayed Price · Currency is AUD | Market Cap | 579.85M +127.9% |
| Revenue (ttm) | 109.32M +1.0% |
| Net Income | -62.28M |
| EPS | -2.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,203 |
| Open | 3.700 |
| Previous Close | 3.680 |
| Day's Range | 3.700 - 3.770 |
| 52-Week Range | 1.000 - 3.840 |
| Beta | 2.02 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About AVITA Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.
Financial numbers in USD Financial StatementsNews
AVITA Medical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership emphasized operational focus and disciplined execution, driving strong sequential growth and improved financials. The company is deepening penetration in existing accounts, expanding its product portfolio, and targeting cash flow breakeven by Q4 2026, with significant market opportunity ahead.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced t...
AVITA Medical Transcript: KOL event
PermeaDerm demonstrated a 70% cost reduction and comparable clinical outcomes to allograft, with high surgeon and patient satisfaction. Surgeons reported workflow and supply advantages, no safety concerns, and broad applicability, supporting a shift toward integrated wound care platforms.
AVITA Medical Press release: KOL event
AVITA Medical issued a press release on August 18, 2026, disclosing material business information to investors.
AVITA Medical Slides: KOL event
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
AVITA Medical Transcript: Investor update
Revenue guidance raised to $86-$89 million for 2026, with cash flow breakeven expected in Q4. Strong sequential revenue growth, stable margins, and disciplined OpEx support this outlook. Nationwide CMS reimbursement changes and international expansion further strengthen growth prospects.
AVITA Medical Slides: Investor update
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
AVITA Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
Sequential revenue growth, raised guidance, and cost discipline position the business for cash flow breakeven by year-end. The three-product portfolio is gaining adoption, supported by strong clinical and economic data, with further growth expected as reimbursement simplifies in 2027.
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholde...
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it...
AVITA Medical Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 18% year-over-year to $21.7 million, driven by strong adoption of RECELL and supporting products. Gross margin remained high at 81.9%, and guidance was raised to $86–$89 million for 2026, with cash flow breakeven expected in Q4.
AVITA Medical Earnings release: Q2 2026
AVITA Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q2 2026
AVITA Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
AVITA Medical Slides: Q2 2026
AVITA Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” ...
AVITA Medical to Announce Second Quarter 2026 Financial Results
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transfor...
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RE...
AVITA Medical Transcript: Status update
Revenue grew 10% sequentially to $19.3 million in Q1, with guidance reaffirmed at $80–$85 million for the year. Operational headwinds have turned to tailwinds, reimbursement issues are resolved, and international expansion is progressing through strong partnerships. Cash runway is sufficient for break-even, with flexibility for future capital needs.
AVITA Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% year-over-year and 10% sequentially, driven by RECELL and Cohealyx adoption, with gross margin at 81.7% and operating expenses down 11%. Full-year guidance of $80–$85 million was reaffirmed, and cash use is expected to decrease in Q2.
AVITA Medical Earnings release: Q1 2026
AVITA Medical released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q1 2026
AVITA Medical has published its Q1 2026 quarterly earnings report on May 14, 2026.
AVITA Medical Slides: Q1 2026
AVITA Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
AVITA Medical Reports First Quarter 2026 Financial Results
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” o...
AVITA Medical Names Cary Vance as Chief Executive Officer
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board...